Testagen (KEDG) – Research Compound Profile

Testagen (KEDG) – Research Compound Profile

Category: Endocrine Research | Molecular Type: Synthetic Tetrapeptide Bioregulator (Lys-Glu-Asp-Gly) | Research Status: Preclinical — No Human Clinical Trials for Isolated KEDG

This page compiles published research data for qualified researchers. Testagen (KEDG) is sold exclusively as a research compound and is not approved for human use.

Purchase for Research →

Molecular Overview

Testagen is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Gly (KEDG), originally derived from anterior pituitary gland extracts. It was developed by Prof. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as part of a broader program of peptide bioregulator research spanning over 35 years [1][2][11]. KEDG belongs to the class of ultrashort bioregulatory peptides (2–4 amino acids) that were first isolated from organ-specific cytomedine preparations by Morozov and Khavinson in the 1980s [11].

Structural characterization studies have confirmed KEDG’s molecular properties and charge distribution [18]. Unlike conventional peptide hormones that require membrane-bound receptor signaling, KEDG is classified among peptides that operate through direct DNA and histone interactions at the nuclear level [2][5]. The closely related polypeptide complex Testoluten — a multi-peptide extract of testicular tissue from which the KEDG sequence was identified — has been the subject of limited clinical investigations in male endocrine function [14].

Mechanism of Action

The mechanism of action of Testagen (KEDG) has been characterized across several peer-reviewed studies as primarily epigenetic rather than receptor-mediated.

Nuclear Penetration and DNA Binding: Fedoreyeva et al. (2011) used fluorescence-labeled KEDG peptides and confirmed that they penetrate into the nuclei and nucleoli of HeLa cells. In vitro binding assays demonstrated that KEDG preferentially binds to CAG-containing DNA sequences [12]. This sequence selectivity suggests targeted gene-regulatory activity rather than nonspecific chromatin interaction.

Histone Interactions: In a 2013 Biochemistry Moscow study, Fedoreyeva et al. demonstrated that KEDG binds to FITC-labeled wheat histones H1, H2b, H3, and H4 at their N-terminal peptide-binding motifs. Notably, binding constants were significantly higher when DNA-histone complexes were methylated, indicating methylation-dependent binding selectivity [5]. This finding is relevant because aging is associated with progressive heterochromatinization — the silencing of previously active gene programs through chromatin condensation [13].

Chromatin Remodeling in Aging: Khavinson et al. (2004) demonstrated in Bulletin of Experimental Biology and Medicine that short peptides, including those in the KEDG class, activated heterochromatin and heterochromatinized regions of cell chromosomes in lymphocytes isolated from elderly human subjects [13]. This observation supports a model in which KEDG may contribute to the reactivation of age-silenced gene programs.

Cellular Transport: Molecular modeling studies published in the International Journal of Molecular Sciences (2022) identified the L-type amino acid transporter LAT1 (SLC7A5) as a primary cellular uptake mechanism for KEDG, with a binding energy of −21.92 kcal/mol [17]. LAT1 is widely expressed in testicular, thyroid, and pituitary tissues, providing a plausible transport pathway to endocrine target cells.

Endocrine Signaling Hypothesis: Based on the above molecular data, researchers have proposed that KEDG enters target endocrine cells via LAT1, translocates to the nucleus, modulates chromatin structure at hormone-synthesis gene loci through methylation-dependent histone binding, and thereby influences age-diminished hormonal output along the hypothalamic-pituitary-gonadal (HPG) axis [1][2][3].

Published Research Parameters

The following table summarizes experimental conditions reported in peer-reviewed publications involving the KEDG tetrapeptide or its parent polypeptide complex (Testoluten). These reflect published research protocols and are not recommendations for any use. Note that no published studies have established dose-response parameters for isolated KEDG administered subcutaneously in humans.

Important Limitation: The majority of dose-response data for KEDG derives from in vitro studies (active at concentrations of 2–200 ng/mL) and in vivo avian models. The two clinical studies cited above (references 14 and 15) utilized the multi-peptide polypeptide complex Testoluten or combined peptide formulations — not isolated KEDG — and therefore cannot be directly extrapolated to the isolated tetrapeptide [2][5].

Analytical Characterization

As a synthetic tetrapeptide, KEDG presents a comparatively simple analytical target relative to longer peptides, but its short length and acidic residue content (Glu, Asp) introduce their own characterization considerations. RP-HPLC with UV detection at 214–220 nm resolves the intact tetrapeptide from truncated fragments and residual synthesis byproducts; because the sequence contains two acidic side chains, reversed-phase retention is sensitive to mobile-phase pH, and a validated method should specify buffer conditions. ESI-MS or MALDI-TOF confirms the monoisotopic mass of the intact Lys-Glu-Asp-Gly sequence and can detect deamidation of the internal glutamate/aspartate residues, a common degradation pathway for short acidic peptides in aqueous solution. Amino acid analysis provides an orthogonal quantitative check on peptide content independent of counter-ion and moisture contribution to gross vial mass, which is particularly relevant for a four-residue peptide where a small absolute mass discrepancy represents a large percentage error.

Stability & Storage Characteristics

Published literature and peptide handling guidelines provide the following stability data relevant to KEDG and short peptides in this class:

• Lyophilized form: Short synthetic peptides in lyophilized form are generally stable for 24+ months when stored at −20 °C (−4 °F) in a dry, dark environment. Repeated temperature fluctuations should be avoided, as they promote moisture absorption and peptide degradation [7][8].
• Reconstituted solution: Once reconstituted in aqueous solution, peptides of this class are generally maintained at 2–8 °C (35.6–46.4 °F), protected from light. Published handling guidelines recommend use within 4 weeks of reconstitution [7].
• Freeze-thaw sensitivity: Freeze-thaw cycles are documented to degrade peptide integrity in solution. If long-term storage of reconstituted material is required, single-use aliquots frozen at −20 °C are recommended in published peptide handling protocols [8].
• Degradation characteristics: As a tetrapeptide (4 amino acids), KEDG is subject to rapid degradation by ubiquitous peptidases in biological systems, which contributes to its reported low-toxicity profile but also presents challenges for sustained-exposure experimental designs [1][6].

Key Published Research Findings

All findings below are attributed to specific published studies. KEDG is classified as a research compound and these observations do not constitute evidence of therapeutic efficacy.

• Thyroid hormone normalization in avian models: In 2011 studies published in Bulletin of Experimental Biology and Medicine, Kuznik et al. demonstrated that administration of KEDG to hypophysectomized chickens (young birds and old hens) significantly normalized thyroid hormone levels — increasing both T₃ and T₄ concentrations — and prevented thyroid gland atrophy and secondary hypothyroidism that otherwise developed following pituitary removal [3][4].

• Testosterone increase with polypeptide complex (Testoluten): In a clinical study described in Russian Federation Patent RU2302874C1 (2006), Khavinson et al. reported that adult male subjects who received Testoluten (a polypeptide complex containing the KEDG sequence) over a short-term study period showed a statistically significant increase in blood testosterone concentration relative to baseline [14]. Note: This study used the multi-peptide complex, not isolated KEDG.

• Combined peptide hormonal effects: At the 2022 IAGG World Congress, Gorgiladze et al. presented findings from a study of adult men, in which a combination of testicular, adrenal, prostate, and pancreatic peptide bioregulators was associated with statistically significant increases in free and total testosterone and a corresponding decrease in cortisol, relative to baseline [15]. These results reflect a multi-peptide intervention and cannot be attributed solely to the KEDG component.

• Thymic morphological recovery: Pateyk et al. (2013) reported in Bulletin of Experimental Biology and Medicine that KEDG promoted morphological recovery of thymic tissue in hypophysectomized birds of all ages, with the anterior pituitary peptide (KEDG) showing more pronounced effects than the posterior pituitary peptide (Ala-Glu-Asp-Gly, AEDG) [16].

• Epigenetic gene reactivation in aging tissue: In a 2004 Bulletin of Experimental Biology and Medicine study, Khavinson et al. demonstrated that short peptides activated heterochromatin and heterochromatinized regions of cell chromosomes in lymphocytes isolated from elderly human subjects, suggesting a capacity to reactivate age-silenced gene programs [13].

• Nuclear penetration and sequence-specific DNA binding: Fedoreyeva et al. (2011) confirmed through fluorescence labeling studies that KEDG penetrates into HeLa cell nuclei and nucleoli, and preferentially binds CAG-containing DNA sequences [12].

• Histone binding with methylation-dependent selectivity: Fedoreyeva et al. (2013) demonstrated in Biochemistry Moscow that KEDG binds to histones H1, H2b, H3, and H4 at N-terminal peptide-binding motifs, with binding constants that are notably higher when DNA-histone complexes are methylated [5].

• Cellular transport via LAT1: Khavinson et al. (2022) identified through molecular modeling that KEDG is transported into cells via the L-type amino acid transporter LAT1 (SLC7A5), with a binding energy of −21.92 kcal/mol. LAT1 is widely expressed in testicular, thyroid, and pituitary tissues [17].

Safety Profile in Published Literature

• No published human safety data exists specifically for the isolated KEDG tetrapeptide. The safety profile in humans has not been established through controlled clinical trials.
• Testoluten toxicity data: Toxicology studies of the Testoluten polypeptide complex (which contains the KEDG sequence) reported no observed adverse effects with single and long-term administration at exposure levels substantially exceeding the study exposure level [14].
• General tetrapeptide safety characteristics: Short peptide bioregulators (2–4 amino acids) are generally considered to have favorable safety profiles in published literature, attributed to their rapid degradation by ubiquitous peptidases and their activity at physiologic (nanomolar) concentrations [1][6].
• Theoretical endocrine considerations: Because KEDG modulates the pituitary–gonadal axis in preclinical models, published authors have noted the potential for endocrine effects that should be monitored in experimental settings, particularly in models with pre-existing thyroid conditions [3][4].
• Data limitations: All safety data for the isolated KEDG tetrapeptide is derived from preclinical models (primarily avian and in vitro). The two clinical studies cited (references 14 and 15) used multi-peptide complexes, and their safety profiles may not be directly applicable to isolated KEDG.

Regulatory Status

• FDA Approval: Testagen (KEDG) has not been approved by the U.S. Food and Drug Administration for any human therapeutic use.
• Clinical Trial Status: No registered clinical trials on ClinicalTrials.gov exist for the isolated KEDG tetrapeptide as of the most recent literature review.
• Research Classification: Testagen is sold exclusively as a research compound for in vitro and preclinical investigation. It is not intended for human consumption, therapeutic application, or diagnostic use.
• Regulatory Context: The Testoluten polypeptide complex (from which KEDG is derived) has been studied under Russian Federation regulatory frameworks, including patent documentation [14], but this does not confer regulatory approval in the United States or other jurisdictions.

References

1. MDPI Molecules (2021) — Khavinson, V.K., Popovich, I.G., Linkova, N.S. et al., “Peptide Regulation of Gene Expression: A Systematic Review.” Comprehensive review identifying KEDG (Testagen) as a regulator of male reproductive system function through DNA–peptide interactions. View Source

2. MDPI Molecules (2021) — Khavinson, V.K. et al., Table 5 classification: KEDG listed as “regulation of male reproductive system function” with references to DNA binding, histone interaction, and immunogenic differentiation. View Source

3. PubMed (2011) — Kuznik, B.I. et al., “Effects of Peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on Hormonal Activity and Structure of the Thyroid Gland in Hypophysectomized Young Chickens and Old Hens.” Demonstrated KEDG normalization of thyroid hormones T₃ and T₄ in pituitary-deficient avian models. View Source

4. PubMed (2011) — Kuznik, B.I. et al., “The effect of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds.” Showed KEDG prevented thyroid atrophy and secondary hypothyroidism. View Source

5. Biochemistry Moscow (2013) — Fedoreyeva, L.I., Smirnova, T.A., Kolomijtseva, G.Y., Khavinson, V.K., Vanyushin, B.F., “Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides.” Demonstrated KEDG binding to histones H1, H2b, H3, H4 with methylation-dependent affinity. View Source

6. Biogerontology (2010) — Anisimov, V.N., Khavinson, V.K., “Peptide bioregulation of aging: Results and prospects.” Review of 35 years of peptide bioregulator research showing substantial increases in mean lifespan with long-term peptide treatment. View Source

7. GenScript — “Peptide Storage and Handling Guidelines.” Reconstitution and stability best practices for lyophilized peptides including temperature management and freeze-thaw avoidance. View Source

8. JPT Peptide Technologies — “How Long Do Peptides Last?” Overview of peptide stability under various storage conditions and degradation pathways for short peptides. View Source

9. Int. J. Immunopharmacol. (1997) — Morozov, V.G., Khavinson, V.K., “Natural and synthetic thymic peptides as therapeutics for immune dysfunction.” Foundational paper on the development of cytomedines and peptide bioregulator extraction methodology. View Source

10. Bull. Exp. Biol. Med. (2011) — Fedoreyeva, L.I., Kireev, I.I., Khavinson, V.K., Vanyushin, B.F., “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Confirmed nuclear penetration of KEDG and preferential binding to CAG-containing sequences. View Source

11. Bull. Exp. Biol. Med. (2004) — Khavinson, V.K., Lezhava, T.A., Monaselidze, J.R. et al., “Effects of short peptides on lymphocyte chromatin in senile subjects.” Demonstrated that short peptides activate heterochromatin and heterochromatinized regions of cell chromosomes in elderly subjects. View Source

12. RF Patent (2006) — Khavinson, V.K., Malinin, V.V., Ryzhak, G.A., “A drug that normalizes reproductive function in men.” Patent describing a Testoluten clinical study in which testosterone increased significantly relative to baseline over a short-term treatment period. View Source

13. IAGG World Congress Abstracts (2022) — Gorgiladze, D.A., Kalendzhyan, V.V., Aleksandrov, V.A., Pinaev, R.N., “Features of the use of gender-specific peptides in middle-aged men.” Study of adult men showing combined peptide therapy was associated with a significant increase in free testosterone. Buenos Aires, Argentina.

14. Bull. Exp. Biol. Med. (2013) — Pateyk, A.V., Baranchugova, L.M., Rusaeva, N.S. et al., “Effect of Peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the Morphology of the Thymus in Hypophysectomized Young and Old Birds.” KEDG promoted thymic structural recovery with more pronounced effects than the posterior pituitary peptide. View Source

15. MDPI Int. J. Mol. Sci. (2022) — Khavinson, V. et al., “Transport of Biologically Active Ultrashort Peptides Using Electroresponsive Nanocapsules.” Identified LAT1 (SLC7A5) as a primary transporter for KEDG with binding energy of −21.92 kcal/mol. View Source

16. MDPI Molecules (2025) — Dobriţescu, A. et al., “The Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces in Saline Environments.” Structural characterization confirming KEDG molecular properties and charge distribution. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Testagen (KEDG) is sold exclusively as a research compound and has not been approved by the FDA for human consumption. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase Testagen for Research →